The China Computed Tomography Market size is estimated at USD 1.34 billion in 2024 and is expected to reach USD 1.79 billion by 2029, registering a CAGR of 5.98% during the forecast period (2024-2029).
During the early stages of the pandemic, the Chinese government imposed a state-wide public transportation freeze, effectively halting all diagnostic department operations. Patients for imaging and therapy in the cardiovascular, dental, oncology, and orthopedic departments were drastically reduced, and procedures were postponed until the situation returned to normal. For instance, according to the study published in the Journal of Cardiovascular Computed Tomography in January 2023, CT was widely employed as a supportive tool in the diagnosis of COVID-19 in China during the early stages of the outbreak. Hence, the COVID-19 pandemic had a favorable impact on the market initially; currently, as the pandemic has subsided, the market has lost some traction. However, it is expected to have stable growth during the forecast period of the study.
Factors, such as the growing burden of chronic diseases and technological advancements in computed tomography are expected to drive the market in the forecast period. For instance, according to the study published in the Chinese Medical Journal in March 2022, in China, there were around 4,820,000 cancer cases and 3,210,000 cancer deaths in 2022. In China, lung cancer is the most frequent type of cancer. Thus, the growing burden of cancer is expected to boost the demand for effective diagnosis devices which is likely to contribute to the market growth.
China has offered many opportunities to the key players in the industry. Therefore, many foreign players are trying to establish their presence in the Chinese market. For instance, in September 2021, Tencent obtained a Class III medical device license for its pneumonia CT imaging software to support triage and assessment, becoming the first internet company in China to obtain a Class III AI medical license. Various strategic initiatives are being undertaken by the major players. These include mergers, acquisitions, collaborations, partnerships, and product launches. Similarly, expansion by the key market player in the facility of manufacturing digital radiographs is expected to boost the market in the country, for instance, In July 2021, FUJIFILM presented the idea of smart imaging and smart hospital in China. In terms of smart imaging, Fujifilm (China) integrated advanced IT technologies such as the Internet, the Internet of Things, sensors, chips, and algorithms with its years of accumulation in medical imaging fields such as X-ray, nuclear magnetic, computed tomography, ultrasound, and optics.
Hence, owing to these factors, the studied market is expected to witness significant growth in the country. However, high cost associated with the CT scan and procedures may hamper the market growth over the forecast period.
Factors such as the high frequency of dental and cardiovascular ailments, orthopedic diseases, and cancer, strategic efforts by leading companies, and huge investments in the healthcare industry are likely to drive segment growth. Additionally, population awareness of CT imaging services is projected to increase market growth.
The country's growing burden of chronic diseases requires imaging diagnosis, which is likely to boost the segment growth. For instance, according to a study published in Biomedical and Environmental Science in July 2022, CVD affected around 330 million individuals in China in 2021. There are 13.00 million, 11.39 million, 8.90 million, 5.00 million, 4.87 million, 2.50 million, 2.00 million, 45.30 million, and 245.00 million patients suffering from stroke, coronary heart disease, heart failure, pulmonary heart disease, atrial fibrillation, rheumatic heart disease, congenital heart disease, lower extremity artery disease, and hypertension, respectively. Thus, the huge burden of cardiac diseases is expected to rise in demand for effective diagnosis and thus boost segment growth.
Strategic collaboration and partnership in the segment propel the market growth in the country. For instance, in April 2021, AstraZeneca and Geneseeq Technology Inc. collaborated strategically to establish the Bio-Diagnostic Innovation Center in China. The collaboration also includes establishing a clinical diagnostics laboratory for creating an integrated and patient-centric disease diagnosis, treatment, and rehabilitation for cancer patients.
Hence, with the abovementioned factors, diagnostic centers are believed to play a crucial role in the computed tomography market in China.
Many neurological disorders share certain characteristics, and a CT scan can aid in proper diagnosis by differentiating the area of the brain affected by the disorder. The ultimate goal of a CT scan is to provide a clearer brain structure for diagnosis. In the majority of brain diseases, such as vertigo, skull fracture, cerebral infarction, Alzheimer's, and epilepsy, CT images aim to distinguish abnormalities in the structure. Moreover, a growing aging population, which is more prone to neurological diseases, is expected to boost the market growth over the forecast period.
According to the data published by the China Alzheimer Report 2022, China's population of Alzheimer's disease patients is about six million, with the percentage of individuals with dementia being 5%, 11.5%, and 30% among 65-, 75-, and 85-year-olds. Further, according to the study published in the Atmospheric Environment in August 2022, In China, about 10 million people had epilepsy in 2021. Epilepsy has neurological, cognitive, psychological, and social consequences. People with epilepsy have a two to four times higher risk of fatal injuries. Thus, the huge burden of neurological diseases is expected to rise in demand for effective diagnosis, which will likely propel the demand for CT in China, boosting the segment growth.
Thus, all factors above are expected to boost the segment growth over the forecast period.
This product will be delivered within 2 business days.
During the early stages of the pandemic, the Chinese government imposed a state-wide public transportation freeze, effectively halting all diagnostic department operations. Patients for imaging and therapy in the cardiovascular, dental, oncology, and orthopedic departments were drastically reduced, and procedures were postponed until the situation returned to normal. For instance, according to the study published in the Journal of Cardiovascular Computed Tomography in January 2023, CT was widely employed as a supportive tool in the diagnosis of COVID-19 in China during the early stages of the outbreak. Hence, the COVID-19 pandemic had a favorable impact on the market initially; currently, as the pandemic has subsided, the market has lost some traction. However, it is expected to have stable growth during the forecast period of the study.
Factors, such as the growing burden of chronic diseases and technological advancements in computed tomography are expected to drive the market in the forecast period. For instance, according to the study published in the Chinese Medical Journal in March 2022, in China, there were around 4,820,000 cancer cases and 3,210,000 cancer deaths in 2022. In China, lung cancer is the most frequent type of cancer. Thus, the growing burden of cancer is expected to boost the demand for effective diagnosis devices which is likely to contribute to the market growth.
China has offered many opportunities to the key players in the industry. Therefore, many foreign players are trying to establish their presence in the Chinese market. For instance, in September 2021, Tencent obtained a Class III medical device license for its pneumonia CT imaging software to support triage and assessment, becoming the first internet company in China to obtain a Class III AI medical license. Various strategic initiatives are being undertaken by the major players. These include mergers, acquisitions, collaborations, partnerships, and product launches. Similarly, expansion by the key market player in the facility of manufacturing digital radiographs is expected to boost the market in the country, for instance, In July 2021, FUJIFILM presented the idea of smart imaging and smart hospital in China. In terms of smart imaging, Fujifilm (China) integrated advanced IT technologies such as the Internet, the Internet of Things, sensors, chips, and algorithms with its years of accumulation in medical imaging fields such as X-ray, nuclear magnetic, computed tomography, ultrasound, and optics.
Hence, owing to these factors, the studied market is expected to witness significant growth in the country. However, high cost associated with the CT scan and procedures may hamper the market growth over the forecast period.
China Computed Tomography Market Trends
Diagnostic Centers to Hold Significant Share in End-User Segment Over the Forecast Period
Diagnostic centers are the major end users of computed tomography and are expected to witness a significant share in the segment.Factors such as the high frequency of dental and cardiovascular ailments, orthopedic diseases, and cancer, strategic efforts by leading companies, and huge investments in the healthcare industry are likely to drive segment growth. Additionally, population awareness of CT imaging services is projected to increase market growth.
The country's growing burden of chronic diseases requires imaging diagnosis, which is likely to boost the segment growth. For instance, according to a study published in Biomedical and Environmental Science in July 2022, CVD affected around 330 million individuals in China in 2021. There are 13.00 million, 11.39 million, 8.90 million, 5.00 million, 4.87 million, 2.50 million, 2.00 million, 45.30 million, and 245.00 million patients suffering from stroke, coronary heart disease, heart failure, pulmonary heart disease, atrial fibrillation, rheumatic heart disease, congenital heart disease, lower extremity artery disease, and hypertension, respectively. Thus, the huge burden of cardiac diseases is expected to rise in demand for effective diagnosis and thus boost segment growth.
Strategic collaboration and partnership in the segment propel the market growth in the country. For instance, in April 2021, AstraZeneca and Geneseeq Technology Inc. collaborated strategically to establish the Bio-Diagnostic Innovation Center in China. The collaboration also includes establishing a clinical diagnostics laboratory for creating an integrated and patient-centric disease diagnosis, treatment, and rehabilitation for cancer patients.
Hence, with the abovementioned factors, diagnostic centers are believed to play a crucial role in the computed tomography market in China.
Neurology Segment is Expected to Hold Significant Share Over the Forecast Period
The factors propelling the segment's growth are an increase in neurological disorders, huge investments by private players in neurology devices, and product launches by the market players.Many neurological disorders share certain characteristics, and a CT scan can aid in proper diagnosis by differentiating the area of the brain affected by the disorder. The ultimate goal of a CT scan is to provide a clearer brain structure for diagnosis. In the majority of brain diseases, such as vertigo, skull fracture, cerebral infarction, Alzheimer's, and epilepsy, CT images aim to distinguish abnormalities in the structure. Moreover, a growing aging population, which is more prone to neurological diseases, is expected to boost the market growth over the forecast period.
According to the data published by the China Alzheimer Report 2022, China's population of Alzheimer's disease patients is about six million, with the percentage of individuals with dementia being 5%, 11.5%, and 30% among 65-, 75-, and 85-year-olds. Further, according to the study published in the Atmospheric Environment in August 2022, In China, about 10 million people had epilepsy in 2021. Epilepsy has neurological, cognitive, psychological, and social consequences. People with epilepsy have a two to four times higher risk of fatal injuries. Thus, the huge burden of neurological diseases is expected to rise in demand for effective diagnosis, which will likely propel the demand for CT in China, boosting the segment growth.
Thus, all factors above are expected to boost the segment growth over the forecast period.
China Computed Tomography Industry Overview
China's computed tomography (CT) market is consolidated due to the presence of a few major players, including Canon Medical Systems Corporation, Koninklijke Philips NV, GE Healthcare, and Siemens Healthineers. These major players hold a significant share in the industry. Most players focus on bringing technologically advanced products into the market to acquire the maximum market share.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD)
6 COMPETITIVE LANDSCAPE
Methodology
LOADING...
